7 completed, 2 active not recruiting, 2 recruiting, 2 terminated. 14 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 14 | Completed 7, Active not recruiting 2, Recruiting 2, Terminated 2, Withdrawn 1 |
| Phase 2 | 8 | Completed 4, Recruiting 2, Active not recruiting 1, Withdrawn 1 |
Follow AL Amyloidosis: new trials by email Literature Review of AL Amyloidosis trials Research Report on AL Amyloidosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elranatamab in Patients With Relapsed or Refractory AL Amyloidosis Elranatamab - AL Amyloidosis | Phase 1 / Phase 2 | Recruiting | Dana-Farber Cancer Institute | 49 | 2024-11-01 | 2026-08-19 |
| Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis Belantamab mafodotin 2.5 mg/kg (8 weeks), Belantamab mafodotin 1.9 mg/kg (8 weeks), Belantamab mafodotin 1.4 mg/kg (12 weeks) - AL Amyloidosis, Amyloidosis | Phase 1 / Phase 2 | Recruiting | University of Texas Southwestern Medical Center | 37 | 2024-02-15 | 2026-08-19 |
| Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) Venetoclax, Dexamethasone, Daratumumab - AL Amyloidosis, Light Chain (AL) Amyloidosis | Phase 1 / Phase 2 | Withdrawn | Alfred Chung, MD | 2024-01-08 | 2025-03-06 | |
| Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis Venetoclax Oral Tablet, 200 mg, FISH assay, Venetoclax Oral Tablet, 400 mg - AL Amyloidosis | Phase 1 / Phase 2 | Active not recruiting | Columbia University | 53 | 2022-10-26 | 2026-10-08 |
| Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis ZN-d5 - Amyloidosis, AL Amyloidosis | Phase 1 / Phase 2 | Completed | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 18 | 2021-11-30 | 2024-09-19 |
| Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis Bortezomib, Cyclophosphamide, Dexamethasone - AL Amyloidosis | Phase 1 | Active not recruiting | Emory University | 11 | 2021-04-28 | 2026-07-14 |
| A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis Melphalan-Flufenamide (Melflufen), Dexamethasone - AL Amyloidosis | Phase 1 | Terminated | Oncopeptides AB | 6 | 2020-08-06 | 2022-03-28 |
| Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis Ixazomib, Cyclophosphamide, Dexamethasone - AL Amyloidosis | Phase 1 / Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 28 | 2017-06-12 | 2022-09-29 |
| Daratumumab for the Treatment of Patients With AL Amyloidosis daratumumab - AL Amyloidosis | Phase 1 / Phase 2 | Completed | Boston Medical Center | 22 | 2017-03-20 | 2021-05-07 |
| Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis Venetoclax, Dexamethasone - AL Amyloidosis | Phase 1 | Terminated | Tufts Medical Center | 3 | 2017-01-01 | 2020-08-21 |
| Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients With AL Amyloidosis Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4 - AL Amyloidosis | Phase 1 | Completed | Alexion Pharmaceuticals, Inc. | 30 | 2014-10-30 | 2025-02-07 |
| A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis Pomalidomide, Dexamethasone - AL Amyloidosis | Phase 1 / Phase 2 | Completed | Boston Medical Center | 27 | 2012-06-01 | 2020-09-22 |
| Radioimmunoimaging of Light Chain (AL) Amyloidosis Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg) - AL Amyloidosis | Phase 1 | Completed | University of Tennessee | 30 | 2008-12-01 | 2013-09-18 |
| Radioimmunoimaging of AL Amyloidosis 124I-labeled monoclonal antibody Mu 11-1F4 - AL Amyloidosis | Phase 1 | Completed | University of Tennessee | 38 | 2008-11-01 | 2012-10-11 |
Immunoglobulin Light-chain Amyloidosis (14) · Amyloidosis (4) · Alzheimer Disease (1) · Proteostasis Deficiencies (1) · Recurrence (1)
Immune System Diseases (14) · Immunoproliferative Disorders (14) · Lymphoproliferative Disorders (14) · Metabolic Diseases (14) · Neoplasms (14) · Neoplasms by Histologic Type (14) · Neoplasms, Plasma Cell (14) · Nutritional and Metabolic Diseases (14) · Paraproteinemias (14) · Proteostasis Deficiencies (13) · Amyloidosis (10) · Brain Diseases (1) · Central Nervous System Diseases (1) · Dementia (1) · Disease Attributes (1)
Dexamethasone (7) · Calcium Dobesilate (4) · daratumumab (3) · venetoclax (3) · Cyclophosphamide (2) · dexamethasone acetate (2) · ixazomib (2) · pomalidomide (2) · Bendamustine Hydrochloride (1) · Biological Assay (1) · Bortezomib (1) · Drug Evaluation (1) · In Situ Hybridization (1) · In Situ Hybridization, Fluorescence (1) · auricularum (1)
Boston Medical Center (2) · University of Tennessee (2) · Alexion Pharmaceuticals, Inc. (1) · Alfred Chung, MD (1) · Columbia University (1) · Dana-Farber Cancer Institute (1) · Emory University (1) · Icahn School of Medicine at Mount Sinai (1) · K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. (1) · Oncopeptides AB (1) · Tufts Medical Center (1) · University of Texas Southwestern Medical Center (1)
United States (13) · Greece (2) · Israel (2) · Spain (2) · Australia (1) · Cyprus (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Norway (1) · United Kingdom (1)
Vaishali Sanchorawala, MD (2) · Alfred Chung, MD (1) · Andrew Eisenberger, MD (1) · Craig C Hofmeister, MD, MPH (1) · Giada Bianchi (1) · Giovanni Palladini, MD (1) · Keren Osman, MD (1) · Larry Anderson, MD (1) · Rajshekhar Chakraborty, MD (1) · Raymond Comenzo, MD (1)
PMID 40226119, PMID 27381904, PMID 31978210, PMID 34521113
P30CA138292 (1)